Meanwhile the sector continues to suck in cash... (FWIW, I would guess that the window will stay open long enough for GLIA to participate.) ... and it's only lunchtime -
SAN DIEGO, Feb. 17 /PRNewswire/ -- Invitrogen Corporation (Nasdaq: IVGN - news) today announced a private placement of $200,000,000 in Convertible Subordinated Notes.
The offering is being made to qualified institutional buyers. The notes, due in 2007, will be convertible into shares of Invitrogen's common stock. The convertible notes will accrue interest that will be payable semiannually. Both the interest rate on the convertible notes and the conversion price will be determined at the time of the closing of the offering, which is expected by the end of February.
Invitrogen has granted the initial purchasers of the convertible notes an option to purchase up to an additional $30 million principal amount of notes to cover over-allotments, if any.
SEATTLE--(BUSINESS WIRE)--Feb. 17, 2000--Cell Therapeutics, Inc. (cti) (Nasdaq:CTIC - news) announced completion of an offering of 3.33 million shares of common stock at a price of $12 per share raising gross proceeds of $40 million.
CONCORD, Calif., Feb. 17 /PRNewswire/ -- Cerus Corporation (Nasdaq: CERS - news) announced today that it has closed the sale of 1,000,000 newly issued shares of its common stock to selected institutional and other accredited investors, including Baxter Healthcare Corporation. The private placement was originally announced on December 21, 1999. A resale registration statement covering these shares is in effect. Prudential Vector Healthcare Group, a unit of Prudential Securities Incorporated, assisted Cerus in the financing. With the completion of this financing, the company has cash and investments of approximately $61.8 million.
MORRIS PLAINS, N.J., Feb. 17 /PRNewswire/ -- Immunomedics, Inc. (Nasdaq: IMMU - news) today announced that it has completed a private placement of 2.325 million shares of Common Stock to a group of investors for gross revenues of $ 37.2 million. The Company intends to file a registration statement in connection with these shares. The offering was managed by Sutro & Co. Incorporated.
PLAINSBORO, N.J., Feb. 17 /PRNewswire/ -- Integra LifeSciences Holdings Corporation (Nasdaq: IART - news) announced that investment affiliates of Soros Private Equity Partners LLC have agreed to invest an additional $5.4 million in Integra LifeSciences. The investment is expected to close by March 31, 2000, subject to the satisfaction of various closing conditions, including early termination or expiration of the Hart- Scott-Rodino waiting period.
WEST BRIDGEWATER, Mass., Feb. 17 /PRNewswire/ -- Boston Biomedica, Inc. (Nasdaq: BBII - news), announced today that the Paradigm Group (Northbrook, Illinois) and certain related parties have exercised outstanding warrants to purchase shares of the Company's common stock at an aggregate exercise price of approximately $2.2 million in cash |
